1, 2-dihydro-3H-dibenzisoquinoline-1,3-dione anticancer agents

A compound of the formula:

• ##STR24## or pharmaceutically acceptable salts thereof wherein R.sub.8 is aminoloweralkyleneoxy, monoloweralkylaminoloweralkyleneoxy, diloweralkylaminoloweralkyleneoxy, or ##STR25## R.sub.6 and R.sub.10 are independently hydrogen, lower alkyl, aryl, lower alkanoyl, formyl, halogen, hydrazino, nitro, NR.sub.2 R.sub.3, heterocyclic lower alkyl, lower alkyl sulfonyl, OR.sub.1, aminoloweralkyleneoxy, monoloweralkylamino-loweralkyleneoxy, diloweralkylaminoloweralkyleneamino, loweralkanoylamino, ##STR26## SR.sub.1, hydroxy, methoxy, cyano, CO.sub.2 H, SO.sub.2 NR.sub.1 R.sub.2, or CONR.sub.1 R.sub.2 ;
• R.sub.1 is hydrogen, lower alkyl, aryl lower alkyl, aryl, formyl or lower alkanoyl;
• R.sub.2 and R.sub.3 are independently hydrogen, lower alkyl, aryl, aryl lower alkyl, formyl, lower alkanoyl, monoloweralkyl amino lower alkylene, diloweralkylamino lower alkylene or hydroxy lower alkyl amino;
• A is (CR.sub.4 R.sub.5)n.sub.3, lower cycloalkylene or arylene or a chemical bond;
• each R.sub.4 and R.sub.5 are independently hydrogen or lower alkyl;
• R.sub.14 and R.sub.15 are independently hydrogen or loweralkyl;
• n.sub.3 is 0, 1, 2, 3, 4 or 5;
• R.sub.12 and R.sub.13 are independently hydrogen, or lower alkyl which is unsubstituted or substituted with hydroxy, mercapto, lower alkoxy, lower alkylcarbonyloxy, carboxy, or carboloweralkoxy or R.sub.12 and R.sub.13 taken together with the a nitrogen to which they are attached form a 3-6 membered heterocyclic ring with said ring containing a nitrogen ring heteroatom and optionally an O or S ring heteroatom;
• and
• D is a chemical bond, or taken together with NR.sub.12 forms a 5 or 6-membered heterocyclic ring with said ring containing nitrogen ring heteroatom and optionally an O or S ring heteroatom.

A compound of the formula ##STR27## or pharmaceutically acceptable salts thereof wherein R.sub.6 is aminoloweralkyleneoxy, monoloweralkylaminoloweralkyleneoxy, diloweralkylaminoloweralkyleneoxy, or ##STR28## R.sub.9 and R.sub.10 are independently hydrogen, lower alkyl, aryl, lower alkanoyl, formyl, halogen, hydrazino nitro, NR.sub.2 R.sub.3, heterocyclic lower alkyl, lower alkyl sulfonyl, OR.sub.1, amino lower alkyleneoxy, monoloweralkylaminoloweralkyleneoxy, diloweralkylaminoloweralkyleneoxy, diloweralkylaminolowerlalkyleneamino, loweralkyanoylamino, ##STR29## SR.sub.1, cyano, CO.sub.2 H, SO.sub.2 NR.sub.1 R.sub.2, or CONR.sub.1 R.sub.2 ;

• R.sub.1 is hydrogen, lower alkyl, aryl lower alkyl, aryl, formyl or lower alkanoyl;
• R.sub.2 and R.sub.3 are independently hydrogen, lower alkyl, aryl, aryl lower alkyl, formyl, lower alkanoyl, monoloweralkyl amino lower alkylene, diloweralkylamino lower alkylene or hydroxy lower alkyl amino;
• A is (CR.sub.4 R.sub.5)n.sub.3, lower cycloalkylene or arylene or a chemical bond;
• each R.sub.4 and R.sub.5 are independently hydrogen or lower alkyl;
• n.sub.3 is 0, 1, 2, 3, 4, or 5;
• R.sub.14 and R.sub.15 are independently hydrogen or lower alkyl;
• R.sub.12 and R.sub.13 are independently hydrogen or lower alkyl, which is unsubstituted or substituted with hydroxy, mercapto, lower alkoxy, lower alkylcarbonyloxy, carboxy, or carboloweralkoxy or R.sub.12 and R.sub.13 taken together with the nitrogen to which they are attached form a 3-6-membered heterocyclic ring, with said ring containing a nitrogen as a ring heteroatom and optionally a sulfur or oxygen ring heteroatom;
• and
• D is a chemical bond, or taken together with NR.sub.12 forms a 5 or 6-membered heterocyclic ring, with said ring containing a nitrogen as a ring heteroatom and optionally a sulfur or oxygen ring heteroatom.

A compound of the formula:

• ##STR30## or pharmaceutically acceptable salts thereof wherein R.sub.10 is aminoloweralkyleneoxy, monoloweralkylaminoloweralkyleneoxy, diloweralkylaminoloweralkleneoxy or ##STR31## R.sub.6 and R.sub.8 are independently hydrogen, lower alkyl, aryl, lower alkanoyl, formyl, halogen, hydrazino, nitro, NR.sub.2 R.sub.3, heterocyclic lower alkyl, lower alkylsulfonyl, OR.sub.1, amino lower alkyleneoxy, monoloweralkylamino-loweralkyleneoxy, diloweralkylaminoloweralkyleneoxy, diloweralkylamino loweralkyleneamino, loweralkyanoylamino, ##STR32## SR.sub.1, cyano, CO.sub.2 H, SO.sub.2 NR.sub.1 R.sub.2, or CONR.sub.1 R.sub.2 ;
• R.sub.1 is hydrogen, lower alkyl, aryl lower alkyl, aryl, formyl or lower alkanoyl;
• R.sub.2 and R.sub.3 are independently hydrogen, lower alkyl, aryl, aryl lower alkyl, formyl, lower alkanoyl, monoloweralkyl amino lower alkylene, diloweralkylamino lower alkylene or hydroxy lower alkyl amino;
• A is (CR.sub.4 R.sub.5)n.sub.3, lower cycloalkylene or arylene or a chemical bond;
• each R.sub.4 and R.sub.5 are independently hydrogen or lower alkyl;
• R.sub.14 and R.sub.15 are independently hydrogen or loweralkyl;
• n.sub.3 is 0, 1, 2, 3, 4 or 5;
• R.sub.12 and R.sub.13 are independently hydrogen or lower alkyl which is unsubstituted or substituted with hydroxy, mercapto, lower alkoxy, lower alkylcarbonyloxy, carboxy, or carboloweralkoxy or R.sub.12 and R.sub.13 taken together with the nitrogen to with they are attached form a 3-6-membered heterocyclic ring, with said ring containing a nitrogen ring heteroatom and optionally an oxygen or sulfur ring heteroatom;
• and
• D is a chemical bond, or taken together with NR.sub.12 forms a 5 or 6-membered heterocyclic ring, said ring containing a nitrogen ring heteroatom, and optionally a sulfur or oxygen ring heteroatom.